Optoceutics ApSAktiv
Økonomiske nøgletal
Nøgletal
2025Balancens sammensætning
Selskabsskat
indkomstår 2024Kilde: Skattestyrelsens offentlige skattelister for selskaber. Beregnet skat for indkomståret; kan være lavere end 22 % af indkomsten, fx ved skat betalt i udlandet. sktst.dk
Regnskabstal2019–2025
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Balance — aktiver | |||||||
| Likvide beholdninger | 1.987.555 | 17.058.107 | 11.913.989 | 9.876.816 | 4.319.273 | 8.913.818 | 4.990.876 |
| Omsætningsaktiver i alt | 2.872.118 | 18.427.891 | 13.296.331 | 12.683.970 | 20.272.800 | 22.418.189 | 14.459.655 |
| Anlægsaktiver i alt | 3.721.843 | 8.841.307 | 13.149.796 | 17.241.949 | 20.542.808 | 23.605.028 | 29.117.866 |
| Aktiver i alt | 6.593.961 | 27.269.198 | 26.446.127 | 29.925.919 | 40.815.608 | 46.023.217 | 43.577.521 |
| Balance — passiver | |||||||
| Kortfristede gældsforpligtelser | 730.643 | 995.580 | 3.569.564 | 2.898.157 | 1.842.715 | 2.098.456 | 9.650.712 |
| Langfristede gældsforpligtelser | — | 8.745.595 | 8.500.000 | — | — | 9.860.705 | 1.606.649 |
| Gældsforpligtelser i alt | 730.643 | 9.741.175 | 12.069.564 | 2.898.157 | 1.842.715 | 11.959.161 | 11.257.361 |
| Selskabskapital | 68.654 | 82.052 | 82.902 | 89.033 | 97.009 | 103.301 | 108.991 |
| Overført resultat | 2.105.622 | 9.771.480 | 3.733.494 | 4.425.156 | 2.718.087 | 9.863.515 | 12.449.039 |
| Årets resultat | 652.067 | -506.333 | -3.880.378 | -3.635.660 | -7.211.522 | -9.184.625 | -8.736.152 |
| Egenkapital i alt | 5.051.729 | 16.247.893 | 13.367.310 | 16.943.109 | 28.914.208 | 34.064.056 | 32.320.160 |
| Resultatopgørelse | |||||||
| Bruttofortjeneste | 889.327 | -131.718 | -2.177.118 | 4.262.725 | 909.636 | -519.340 | -2.585.556 |
| Resultat af primær drift | 823.430 | -952.574 | -5.417.711 | — | — | -9.306.110 | -8.440.215 |
| EBITDA | — | — | — | — | — | -8.565.975 | -7.700.080 |
| Resultat før skat | 822.040 | -1.029.740 | -5.486.196 | -5.051.935 | -8.633.470 | -10.068.237 | -9.205.326 |
| Årets resultat | 652.067 | -506.333 | -3.880.378 | -3.635.660 | -7.211.522 | -9.184.625 | -8.736.152 |
| Personaleomkostninger | 65.897 | 820.856 | 3.240.593 | 7.568.539 | 8.424.683 | 8.046.635 | 5.114.524 |
| Af- og nedskrivninger | — | — | — | 750.000 | 535.656 | 740.135 | 740.135 |
| Andre nøgletal | |||||||
| Ansatte | 6 | 6 | 10 | 14 | 14 | 11 | 7 |
En streg (—) betyder, at der ikke er indsendt årsrapport, eller at posten ikke fremgår af den; 0 er et nul angivet i årsrapporten.
Om virksomheden
Årsrapport 2025The company's primary activities has been at the forefront of medical research and innovation since 2018, driven by a vision to address neurological and psychiatric diseases. Our primary focus is on targeting electrical signaling deficits in the brain, with the end goal of developing treatments for conditions such as Alzheimer's disease and dementia.
The results of the company's activities in the financial year amounted to a profit/loss of DKK -8.736.152 against DKK -9.184.625 in last financial year. The equity at the balance sheet date amounted to DKK 32.320.160. In 2025, Optoceutics Continued significant progress in customer and economic product validation, IP portfolio and product development, and clinical validation.Despite the challenges of a traditional startup, we remain dedicated to advancing preventative care before symptoms arise. Our journey is marked by innovation, compassion, and a steadfast commitment to excellence. As we look to the future, we pledge to continue delivering on our goals, benefiting patients, families, society, and shareholders. We extend our gratitude to all who have trusted in our vision and team. Thank you for joining us on this journey.
Uddrag af ledelsesberetningen i den seneste årsrapport.